secnidazole
Trade name: solosec
Approved
Sep 15, 2017
Secnidazole (trade names Flagentyl, Sindose, Solosec) is a nitroimidazole derivative used to in the treatment of amoebiasis and bacterial vaginosis. Secnidazole and other 5-nitroimidazole drugs enter micro-organisms by passive diffusion and undergo activation by reduction of the 5-nitro group. In anaerobic micro-organisms, such as Trichomonas, Giardia and Entamoeba spp., this intracellular reduction occurs via the pyruvate ferredoxin oxidoreductase complex and results in a concentration gradient across the cell membrane which, in tum, enhances transport of the parent drug into the cell. Because the electron affinity of the 5-nitroimidazoles is greater than that of reduced ferredoxin, the drug interrupts the normal electron flow. Aerobic micro-organisms have a more positive redox potential (i.e. are more efficient electron acceptors) than secnidazole and other 5-nitroimidazoles, which explains the selective toxicity of these drugs against anaerobic microorganisms. DNA is the intracellular target of the Secnidazole and other 5-nitroimidazoles. Secnidazole and other 5-nitroimidazoles possess selective activity against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In general, secnidazole and metronidazole were approximately equipotent in activity against Bacteroides fragilis, Trichomonas vaginalis, and Entamoeba histolytica, in in vitro studies. Secnidazole is rapidly and completely absorbed after oral administration. Plasma drug concentrations are linear over the therapeutic dose range of 0.5 to 2g. The tolerability profile of secnidazole does not differ markedly from other 5-nitroimidazoles. The most commonly reported adverse events in clinical trials involved the gastrointestinal tract (nausea, vomiting, glossitis, anorexia, epigastric pain and a metallic taste) and occurred in 2 to 10% of patients. A headache and dizziness were experienced by about 2% of patients. The drug was equally well tolerated in adults and children, and no adverse event required therapeutic intervention or treatment withdrawal. — NCATS
Clinical trial activity
11 trials · 12 clinical orgs · 3 marketing orgs
Earliest trial started Jun 1, 2003 (NCT00607074)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2010
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2014
Symbiomix Therapeutics — Earliest Phase 2 Sponsor(trial)
- Sep 15, 2017
Symbiomix Therapeutics — Earliest FDA Approval
- Sep 15, 2017
Lupin — NDA Secondary Org
- Sep 15, 2017
Symbiomix Therapeutics — NDA Organization
- Sep 15, 2017
Evofem Inc. — Marketing Organization
Indications
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Enters bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis
Approval history
- approvedPriority reviewFast trackSep 15, 2017
Chemistry & pharmacology
SMILES
CC(O)CN1C(C)=NC=C1[N+]([O-])=O- Mol. weight
- 185.1805 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaSecnidazole ↗
- NCATSR3459K699K ↗
- ChEMBLCHEMBL498847 ↗
Also known as
- 1-(2 hydroxypropyl)-2-methyl-5-nitroimidazole
- 1-(2 hydroxypropyl)-2-methyl-5-nitroimidazole
- 1-(2'-hydroxypropyl)-2-methyl-5- nitroimidazole
- 1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2 ol
- 1-(2-methyl-5-nitro-1h-imidazol-1-yl) propan-2 ol
- 14,539 rp
- flagentyl
- minovag
- pm-185184
- pm-185184
- rp-14539
- rp-14539
- sabima
- secnidal
- secnidazol
- secnidazol
- secnidazol
- secnidazol
- secnidazole
- secnidazole
- secnidazole
- secnidazole
- secnidazole
- secnidazole
- secnidazole
- secnidazole
- secnol
- seknidazol
- sym-1219
- sym-1219
- sym-1219
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06261840 | Phase 4 | Jul 1, 2024 | Louisiana State University, Tulane University, University of Alabama, Birmingham |
| NCT05033743 | Phase 2/Phase 3 (Phase 3) | Jul 9, 2021 | Indiana University, Lupin |
| NCT03935217 | Phase 3 | Apr 23, 2019 | Lupin |
| NCT03937869 | Phase 4 | Nov 12, 2018 | Lupin |
| NCT02452866 | Phase 3 | Jun 1, 2015 | Symbiomix Therapeutics |
| NCT02418845 | Phase 3 | May 1, 2015 | Symbiomix Therapeutics |
| NCT02147899 | Phase 2 | May 1, 2014 | Symbiomix Therapeutics |
| NCT02111629 | Phase 3 | May 1, 2012 | Universidad Nacional de Colombia |
| NCT01733966 | Phase 3 | May 1, 2010 | Laboratoires Iprad, QuantaBio |
| NCT01019083 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2008 | International Center for Diarrheal Disease Research, University of Gothenburg |
| NCT00607074 | N/A | Jun 1, 2003 | University of Cambridge |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lupin | For profit | 3 | 2 | 2 | 2018 |
| Symbiomix Therapeutics | For profit | 3 | 3 | 2 | 2014 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Laboratoires Iprad | For profit | 1 | 0 | 1 | 2010 |
| Louisiana State University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| QuantaBio | For profit | 1 | 1 | 1 | 2010 |
| Tulane University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Universidad Nacional de Colombia | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Gothenburg | Academic/Hospital | 1 | 0 | 1 | 2008 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Evofem Inc. | For profit | MKTG | Sep 15, 2017 |
| Lupin | For profit | NDA2 | Sep 15, 2017 |
| Symbiomix Therapeutics | For profit | NDA | Sep 15, 2017 |